טוען...
Ticagrelor – toward more efficient platelet inhibition and beyond
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist...
שמור ב:
| הוצא לאור ב: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5775739/ https://ncbi.nlm.nih.gov/pubmed/29398917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S152369 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|